BioSpace News Archive

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update.

Physicians and scientists alone can’t save American lives from being lost to COVID-19.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced a two-day summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, August 18, and

Even as older adults (ages 65+) generally face higher risk for severe illness and death from COVID-19, the pandemic is taking a much greater emotional toll on America’s younger “Sandwich Generation,” according to new research released today by MDVIP and Ipsos.

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has resumed at certain clinical sites in the U.S. after being temporarily paused in response to the COVID-19

Blade Therapeutics today announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients. Started in May 2020

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Directors

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business.

Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of Schedule Announced Partnership with I-SPY to Participate in a Clinical Trial to Treat ARDS in COVID-19 Patients Announced a Second Clinical Trial Funded in Part by the U.S. Military to Prevent ARDS in COVID-19 Patients Ended Second Quarter 2020 with $44.9 Million in Cash Conference Call Today, August 12, 2020 at 8:30 a.m. EDT

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Gregory Schultz, Ph.D., has been appointed as a Scientific Advisor. Dr. Schultz is the Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. Throughout his career, he has conducted research focusing on the molecular and cellular regulators of normal wound healing and developing t